These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25072509)

  • 21. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats.
    Kobuchi S; Katsuyama Y; Ito Y
    Xenobiotica; 2020 Feb; 50(2):223-230. PubMed ID: 30938550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus.
    Gusella M; Ferrazzi E; Ferrari M; Padrini R
    Ther Drug Monit; 2002 Jun; 24(3):425-31. PubMed ID: 12021636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonlinear pharmacokinetics of 5-fluorouracil in rats.
    Jarugula VR; Lam SS; Boudinot FD
    J Pharm Sci; 1997 Jun; 86(6):756-8. PubMed ID: 9188061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
    Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
    J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
    Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
    Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.
    Saleem A; Aboagye EO; Matthews JC; Price PM
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):865-73. PubMed ID: 17639391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
    Zandvliet AS; Siegel-Lakhai WS; Beijnen JH; Copalu W; Etienne-Grimaldi MC; Milano G; Schellens JH; Huitema AD
    Clin Pharmacol Ther; 2008 Jun; 83(6):829-39. PubMed ID: 17851564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Maekawa C; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Nov; 23(11):1363-9. PubMed ID: 11085367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.
    Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
    J Pharmacol Exp Ther; 2007 May; 321(2):598-607. PubMed ID: 17283225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.
    Ibrahim T; Di Paolo A; Amatori F; Mercatali L; Ravaioli E; Flamini E; Sacanna E; Del Tacca M; Danesi R; Amadori D
    J Clin Pharmacol; 2012 Mar; 52(3):361-9. PubMed ID: 21383342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Sawada S; Nishide T; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Jan; 23(1):87-96. PubMed ID: 10706418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
    Boisdron-Celle M; Craipeau C; Brienza S; Delva R; Guérin-Meyer V; Cvitkovic E; Gamelin E
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):235-43. PubMed ID: 11935216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
    Fukushima K; Okada A; Sasaki K; Kishimoto S; Fukushima S; Hamori M; Nishimura A; Shibata N; Shirai T; Terauchi R; Kubo T; Sugioka N
    J Pharm Sci; 2016 Jan; 105(1):324-32. PubMed ID: 26852862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic model for chemotherapy-induced anemia in rats.
    Woo S; Krzyzanski W; Jusko WJ
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):123-33. PubMed ID: 17891399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.
    Chanu P; Gieschke R; Charoin JE; Pannier A; Reigner B
    J Clin Pharmacol; 2010 May; 50(5):507-20. PubMed ID: 20179322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.